California
Santa Ana; Apex Research Institute
Why Do My Legs Hurt? You may have Peripheral Arterial Disease
Stanford; Stanford University Medical Center
NO PAIN Study: a double blind, placebo-controlled study of L-arginine in the treatment of peripheral arterial disease
Georgia
Atlanta; Emory Surgery Research
A six-month study using an FDA approved high blood pressure medication to evaluate its usefulness in lower leg circulation problems (intermittent claudication)
Indiana
Merrillville; Cardiovascular Clinics, P.C.
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Merrillville; Cardiovascular Clinics, P.C.
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Merrillville; Cardiovascular Clinics, P.C.
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Michigan
Grand Rapids; Spectrum Health Research Department
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Grand Rapids; Spectrum Health Research Department
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Missouri
St. Louis; Saint Louis University
Peripheral Arterial Disease with Intermittent Claudication (leg pain/cramping/aching/numbness experienced while walking that goes away with rest) - Study to evaluate an investigational medication in patients with intermittent claudication.
New Jersey
Long Branch; Monmouth Medical Center
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Long Branch; Monmouth Medical Center
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
New York
New York; Mount Sinai Medical Center
SIMPADICO: Protocol 0101
New York; Mount Sinai Medical Center
Genetic Determinants of Peripheral Arterial Disease
North Carolina
Winston-Salem; Forsyth Medical Center
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Ohio
Toledo; Medical University of Ohio
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Toledo; Medical University of Ohio
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Pennsylvania
Harrisburg; Central Pennsylvania Cardiovascular Research Institute
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Philadelphia; University of Pennsylvania Health System
Do you experience calf pain when walking? If so, you may qualify for an experimental research study at the University of Pennsylvania.
Wisconsin
Marshfield; Marshfield Clinic
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
International
Toronto, Ontario, Canada; University Health Network
Study of the Ability of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Karlsbad, Germany; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Bydgoszcz, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Konskie, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Krakow, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Lublin, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Lublin, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Poznan, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Poznan, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Szczecin, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Szczecin, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Warszawa, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Warszawa, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Warszawa, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Warszawa, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Wroclaw, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Zamosc, Poland; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Chelyabinsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Ekaterinburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Irkutsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Jaroslavl, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kemerovo, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Lipetsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Moscow, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Moscow region, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Moscow region, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Novosibirsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Novosibirsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Omsk, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Rjazan, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Rostov-on-Don, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Rostov-on-Don, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Rostov-on-Don, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Rostov-on-Don, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Saratov, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
St Petersburg, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Tumen, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Tver, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Volgograd, Russian Federation; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Dnepropetrovsk, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Donetsk, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Donetsk, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kiev, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kiev, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kiev, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kiev, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Kiev, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Lviv, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Zaporozhye, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
Zaporozhye, Ukraine; UCB Clinical Trial Call Center
Alprostadil in PAOD Stage IV
